ORIGINAL RESEARCH

Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer

Naoya Nishioka1,2  |  Tateaki Naito1  |  Akifumi Notsu3  |  Keita Mori3  |  Hiroaki Kodama1  |  Eriko Miyawaki1  |  Taichi Miyawaki1  |  Nobuaki Mamesaya1  |  Haruki Kobayashi1  |  Shota Omori1  |  Kazushige Wakuda1  |  Akira Ono1  |  Hirotugu Kenmotsu1  |  Haruyasu Murakami1  |  Koichi Takayama2  |  Toshiaki Takahashi1

1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
2Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
3Division of Clinical Research Management Office, Shizuoka Cancer Center, Shizuoka, Japan

Correspondence
Tateaki Naito, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimo-Nagakubo, Nagazumi-Chou, Sunto-Gun, Shizuoka Pref. 411-8777, Japan.
Email: t.naito@scchr.jp

Abstract

Background: Quantitative skeletal muscle mass loss has the potential to predict the therapeutic effects of immune checkpoint inhibitors. This study aimed to assess the impact of muscular quality on the abovementioned outcomes.

Methods: This study retrospectively reviewed the medical records of patients with advanced non-small cell lung cancer (NSCLC) who had received PD-1/PD-L1 inhibitor monotherapy between March 2016 and February 2018. High muscle quality was stipulated as a skeletal muscle density ≥41 and ≥33 Hounsfield units in patients with a body mass index (BMI) <25 kg/m² and ≥25 kg/m², respectively, as assessed using lumbar computed tomography images. High muscle quantity was stipulated as a lumbar skeletal muscle index ≥41 cm²/m² in women, ≥43 cm²/m² in men with a BMI <25 kg/m², and ≥53 cm²/m² in men with a BMI ≥25 kg/m². We evaluated the associations of these muscular parameters with the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).

Results: Out of 156 patients, 80 (51.3%) and 47 (30.1%) showed low muscle quality and quantity, respectively. Patients with high muscle quality showed higher ORR (35.0 vs. 15.8%, p<0.05) and longer PFS durations (median, 4.5 vs. 2.0 months, p<0.05) than those with low muscle quality. There were no noted differences in the ORR or PFS between patients with high and those with low muscle quantities. On the contrary, regardless of muscle quality and quantity, there were no differences in OS between patients with high and those with low muscle status.

Conclusions: Lumbar skeletal muscle quality has the potential to predict the therapeutic effect of anti-programed cell death 1/programed cell death ligand 1 inhibitor monotherapy in patients with advanced NSCLC.

KEYWORDS
muscle quality, muscle quantity, myosteatosis, non-small cell lung cancer, PD-1/PD-L1 inhibitor

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
1 | BACKGROUND

Immune checkpoint inhibitors exert a therapeutic effect under any condition with an appropriate balance between tumor immunogenicity and host immunity in patients with cancer. Recent reports on the predictors of the therapeutic effects of immune checkpoint inhibitors predominantly focused on tumor antigenicity and the effect of regulatory or suppressor molecules on tumor cells. There are no data on clinically useful predictors for host antitumor immunity. Recently, we proposed a hypothesis regarding the suppressive effects of cancer cachexia on PD-1/PD-L1 inhibitors in patients with metastatic non-small cell lung cancer (NSCLC). Patients with cachexia exhibited worse overall response rate (ORR) and progression free survival (PFS) values than those without it, even if they were potentially sensitive to anti-programed cell death 1/programed cell death ligand 1 (PD-1/PD-L1) inhibitor and have high PD-L1 expression in cancer cells. Impaired nutritional status potentially attenuated the host antitumor immunity in a preclinical study, and several other studies that measured the bodyweight of patients with NSCLC supported our findings.

However, results on the predictive impact of quantitative or qualitative skeletal muscle loss, which are hallmarks of cancer cachexia, are inconsistent. Several articles, including ours, have reported that decreased muscle quantity, as evaluated by computed tomography (CT), is correlated with poor clinical outcomes in patients who use a PD-1/PD-L1 inhibitor. However, the definitions and measurement methods of muscle depletion varied across studies, and the association was not always positive. While some studies reported a negative correlation between muscle quality and the therapeutic effect of PD-1/PD-L1 inhibitors, the results were not definitive. Besides, the majority of these studies estimated the impact of muscle quantity or quality without adjusting for previously reported factors, including PD-L1 expression and pretreatment performance status (PS).

Accordingly, the present study aimed to evaluate whether the quantitative or qualitative loss of lumbar skeletal muscle is predictive of the efficacy of PD-1/PD-L1 inhibitors, regardless of confounding factors, in patients with advanced NSCLC.

2 | METHODS

Consecutive patients with pretreated advanced NSCLC who had undergone PD-1/PD-L1 inhibitor monotherapy between March 2016 and February 2018 in Shizuoka Cancer Center were evaluated. The eligibility criteria were as follows: (a) histologically proven stage III or IV NSCLC, including postoperative recurrence, with reference to the seventh or eighth edition of tumor–node–metastasis staging; (b) Eastern Cooperative Oncology Group (ECOG) PS0-2; (c) presence of at least one measurable lesion; (d) prior treatment history with at least one chemotherapy regimen before PD-1/PD-L1 inhibitor therapy use; (e) no prior immunotherapy; and (f) availability of evaluable lumbar CT images taken within 1 month before the initiation of PD-1/PD-L1 inhibitor therapy. Patients with pretreatment interstitial lung disease were defined as ineligible for this study.

3 | Data collection

The following data were collected from the medical records of eligible patients: age, sex, PS just before the initiation of PD-1/PD-L1 inhibitor therapy, histology, stage, PD-L1 tumor proportion score (TPS) and driver oncogenes when available, number and types of prior treatments, and the type of PD-1/PD-L1 inhibitor received. Pretreatment and previously measured body weight values (measured 6 months before the treatment) were collected, and the body mass index (BMI) and weight changes were calculated. Moreover, neutrophil-to-lymphocyte ratios (NLRs), which reflect inflammation, were collected with blood test data just before the initiation of PD-1/PD-L1 inhibitor therapy. NLR was calculated as neutrophils divided by lymphocytes, and a high NLR was stipulated as an NLR ≥5. Cancer cachexia was stipulated as an unintentional weight loss >5% during the preceding 6 months or >2% in patients with a BMI <20 kg/m², or the presence of muscle depletion according to the consensus criteria.

3.1 | Driver oncogenes and PD-L1 analysis

The status of ALK translocation and EGFR mutation was assessed in all patients with non-squamous NSCLC, while the BRAF mutation and ROS-1 translocation status was assessed in some patients, as appropriate. The PD-L1 TPS values were calculated by trained pathologists using the 22C3 or 28-8 pharmDx assay (SRL, Inc.).

3.2 | Analysis of skeletal muscle

The cross-sectional area of the lumbar skeletal muscle at the third level of the lumbar vertebra (L3) was analyzed using electronically stored CT scans that were taken before the initial administration of PD-1/PD-L1 inhibitors, with or without contrast enhancement within a 5-mm slice thickness. Lumbar skeletal muscles were identified based on Hounsfield unit (HU) thresholds of −29 to +150. All analyses were
performed using slice-O-matic software v5.0 (Tomovision). Muscle quality was calculated as the mean value of the muscular density (HU) in two consecutive images of the cross-sectional skeletal muscle area at the L3 level. High muscle quality was stipulated as a skeletal muscle with density ≥41 HU and ≥33 HU in patients with a BMI <25 and ≥25 kg/m², respectively (see Table S1). Muscle quantity was reported as the lumbar skeletal muscle index (cm²/m²) and calculated as [cross-sectional area of skeletal muscle (cm²)/height² (m²)]. High muscle quantity was defined as a lumbar skeletal muscle index ≥41 cm²/m² in women, ≥43 cm²/m² in men with a BMI <25 kg/m², and ≥53 cm²/m² in men with a BMI ≥25 kg/m².

3.3 Statistical methods

The primary outcome was PFS, which was defined as the period between the first day of PD-1/PD-L1 inhibitor administration and the day of tumor progression or death, whichever occurred first. The final follow-up was on July 3, 2019. The secondary outcome was overall survival (OS) and ORR. We defined OS as the period between the first day of PD-1/PD-L1 inhibitor administration and the day of death from any cause. Median PFS and OS were assessed by the Kaplan–Meier method. Data for patients without disease progression or who were lost to follow-up were censored at the time of the last CT scan for PFS assessment. For PFS and period of response, data for patients in whom treatment with new anticancer agents were initiated patients in whom treatment with new anticancer agents were initiated without recognizing tumor progression were censored on the day of the final tumor assessment before treatment with new anticancer agents was initiated. Data for patients who were alive or lost to follow-up were censored for OS when they were last known to be alive. Log-rank tests were used to compare the PFS and OS curves. According to the Response Evaluation Criteria in Solid Tumors, ORR was measured as the ratio of the sum of complete response and partial response. Potential predictors were assessed using Cox proportional hazards models for PFS. For the crude hazard ratio, the covariates included PD-L1 expression (TPS ≥50% vs. <50% or unknown), ECOG-PS (0–1 vs. 2), muscle quality (high vs. low), muscle quantity (high and low), NLR (≥5 vs. <5), and number of prior treatments (1 vs. ≥2 regimens). The hazard ratio for muscle quality was adjusted for PD-L1 expression and ECOG-PS. Fisher’s exact test and the Wilcoxon test were performed to compare various characteristics between the low and high muscle quality groups. All p-values were two-sided, and a p-value <0.05 was considered statistically significant. All statistical analyses were performed using R. We analyzed the data using the statistical package R version 3.6.3 (https://cran.r-project.org/src/base/R-3/).

4 RESULTS

4.1 Patient characteristics

Out of 279 consecutive patients with advanced NSCLC who initially received PD-1/PD-L1 inhibitor therapy between March 2016 to February 2018, 156 were finally enrolled in this study (Figure 1). Reasons for ineligibility included the following: (a) receipt of PD-1/PD-L1 inhibitors as the first-line treatment (n = 57), (b) CT was not performed within 1 month before PD-1/PD-L1 inhibitor initiation (n = 38), (c) CT did not include the L3 level (n = 26), and (d) patients had no target lesion (n = 2). The patients’ median age was 67 (range, 33–85) years (Table 1). The majority of the patients were men, had a PS of 0–1, and had a non-squamous histology without specific driver oncogenes. Seventy-four (47.4%) and 82 (52.6%) patients had received PD-1/PD-L1 inhibitor therapy as the second- and third-line or greater treatment regimen, respectively. All patients had initiated PD-1/PD-L1 inhibitors as monotherapy, including nivolumab in 75 (48.1%) patients, pembrolizumab in 61 (39.1%) patients, and atezolizumab in 20 (12.8%) patients. The pretreatment PD-L1 TPS was measured in the tissue samples of 109 (69.9%) patients and classified into the following three groups: (a) TPS of ≥50% in 36 (23.1%) patients, (b) TPS between 1% and 49% in 36 (23.1%) patients, and (c) TPS of 0% in 37 (23.7%) patients. Either the PD-L1 level was not measured or the tumor samples could not be used in evaluating the PD-L1 TPS in 47 (30.1%) patients who were categorized as having an unknown PD-L1 status. Sixty-seven (43.0%) patients had a diagnosis of cancer cachexia at baseline. Eighty (51.3%) and 48 (30.8%) patients had a high muscle quality and quantity at the baseline, respectively. No significant differences were found regarding characteristics between patients with high and those with low muscle quality values, except for median age (65.5 vs. 69 years, p < 0.05) and mean attenuation (45.0 ± 4.74 vs. 32.8 ± 5.13 HU, p < 0.05). Out of patients with a high muscle quality, 30 (39.5%) and 58 (72.5%) patients had cancer cachexia and a low muscle quantity, respectively.

4.2 Impact of muscle quality and quantity on tumor response

The ORR was 25.6% in all patients (95% confidence interval [CI], 1.26–6.80). Patients with high tumor PD-L1 expression (TPS ≥50%) had a higher ORR than those with low or unknown PD-L1 expression (50.0% vs. 18.3%, p < 0.05). Patients with a high muscle quality had a higher ORR than those with a low muscle quality (35.0% vs. 15.8%, p < 0.05). Conversely, no difference in the ORR was noted between patients with high
and those with low muscle quantity values (24.8% vs. 27.7%, $p = 0.70$). We further assessed the response rate for each muscle quality group. There was no difference in the ORR in the high muscle quality group between patients with high and those with low muscle quantity values (40.9% vs. 32.8%, $p = 0.60$). Similarly, in the low muscle quality group, no difference in the ORR was noted between patients with high and those with low muscle quantity values (16.0% vs. 15.7%, $p = 1.00$).

### 4.3 Impact of muscle quality and quantity on progression-free survival

Out of the 156 patients, 133 (85.3%) showed tumor progression up to the cutoff date (July 3, 2019). After a median follow-up of 2.5 months (95% CI, 2.0–4.2 months), patients with high tumor PD-L1 expression (TPS $\geq 50\%$) had a longer PFS duration than those with low or unknown PD-L1 expression (6.3 vs. 2.1 months in median, $p < 0.05$). Patients with high muscle quality had a longer PFS than those with low muscle quality (4.5 vs. 2.0 months, $p < 0.05$, Figure 2A). No significant difference in the PFS was noted between patients with high vs. low muscle quantity values (2.5 vs. 2.6 months, $p = 0.95$, Figure 2B). In the multivariate analyses, high muscle quality was significantly associated with superior PFS values, and the adjusted hazard ratio for high muscle quality was 0.67 (95% CI, 0.42–0.89; $p < 0.05$), after adjusting for PD-L1 expression, pretreatment PS, and number of prior treatments (Table 2).

### 4.4 Impact of muscle quality and quantity on OS

Of the 156 patients, 105 (67.3%) had died before the cutoff date (July 3, 2019). After a median follow-up of 11.2 (range, 0.4–42) months, no significant difference in OS was noted between patients with high and those with low muscle quality values (14.1 vs. 11.9 months, $p = 0.30$, Figure 3A). Similarly, there was no significant difference in OS between patients with high and those with low muscle quantity values (15.9 vs. 12.2 months, $p = 0.51$, Figure 3B).

### 5 DISCUSSION

This study suggests that lumbar muscle quality can serve as a sensitive predictor of the therapeutic effects of PD-1/PD-L1 inhibitors.
| Characteristics          | Total (n = 156) | High muscle quality<sup>e</sup> group (n = 80) | Low muscle quality group (n = 76) | p-value |
|-------------------------|----------------|-----------------------------------------------|---------------------------------|---------|
| Age median (range)      | 67 (33–85)     | 65.5 (33–81)                                 | 69 (44–85)                      | p < 0.05|
| Gender (%)              | 101 (64.7)     | 55 (68.8)                                     | 46 (60.5)                       | NS      |
|                         | 55 (35.3)      | 25 (31.2)                                     | 30 (39.5)                       |         |
| ECOG-PS (%)             | 0              | 24 (15.4)                                     | 12 (15.0)                       | NS      |
|                         | 1              | 115 (73.7)                                    | 63 (78.8)                       | p < 0.05|
|                         | 2              | 17 (10.9)                                     | 5 (6.2)                         |         |
| Histology (%)           | Squamous       | 22 (14.1)                                     | 10 (12.5)                       | NS      |
|                         | Non-squamous   | 134 (85.9)                                    | 70 (87.5)                       |         |
| Stage (%)               | III            | 33 (21.2)                                     | 17 (21.2)                       | NS      |
|                         | IV             | 123 (78.8)                                    | 63 (78.8)                       |         |
| Driver oncogene (%)     | EGFR mutation  | 27 (17.3)                                     | 12 (15.0)                       | NS      |
|                         | ALK rearrangement | 1 (0.6)                                      | 0 (0.0)                         | 1 (1.2) |
|                         | Others<sup>a</sup> | 128 (82.1)                                   | 68 (85.0)                       | 60 (78.9)|
| PD-L1 Tumor proportion score (%) | ≥50% | 36 (23.1)                                    | 21 (26.2)                       | 15 (19.7)| NS      |
|                         | 1~49%          | 36 (23.1)                                     | 19 (23.8)                       | 17 (22.4)|         |
|                         | 0%             | 37 (23.7)                                     | 16 (20.0)                       | 21 (27.6)|         |
|                         | Unknown        | 47 (30.1)                                     | 24 (30.0)                       | 23 (30.3)|         |
| Number of prior treatment (%) | 1 | 74 (47.4)                                     | 44 (55.0)                       | 30 (39.5)| NS      |
|                         | ≥2             | 82 (52.6)                                     | 36 (45.0)                       | 46 (60.5)|         |
| Initial PD-1/PD-L1 inhibitor (%) | Nivolumab | 75 (48.1)                                     | 37 (46.2)                       | 38 (50.0)| NS      |
|                         | Pembrolizumab  | 61 (39.1)                                     | 34 (42.6)                       | 27 (35.5)|         |
|                         | Atezolizumab   | 20 (12.8)                                     | 9 (11.2)                        | 11 (14.5)|         |
| BMI (kg/m², mean ± SD)  | 21.9±3.39      | 21.3±4.32                                     | 22.5±3.07                       | NS      |
| Neutrophil-to-lymphocyte ratios<sup>b</sup> | High (≥5) | 35 (22.4)                                     | 18 (22.5)                       | 17 (22.4)| NS      |
|                         | Low (<5)       | 121 (77.6)                                    | 62 (77.5)                       | 59 (77.6)|         |
| LSMI (cm²/m², mean ± SD) | 41.0±7.80    | 41.6±8.44                                     | 40.3±7.07                       | NS      |
| Mean attenuation (HU, mean ± SD) | 39.0±7.85 | 45.0±4.74                                     | 32.8±5.13                       | p < 0.05|
| Pretreatment cachexia<sup>c</sup> (%) | 67 (43.0) | 30 (39.5)                                     | 37 (46.2)                       | NS      |
| Pretreatment muscle quantity<sup>d</sup> (%) | High | 47 (69.9)                                     | 22 (27.5)                       | 25 (32.9)| NS      |
|                         | Low            | 109 (69.9)                                    | 58 (72.5)                       | 51 (67.1)| NS      |

Abbreviation; ECOG-PS, Eastern Cooperative Oncology Group performance status; PD-L1, programed cell death protein ligand 1; PD-1, programed death-1; BMI, body mass index; ns, not significant; EGFR, Epidermal Growth Factor Receptor; ALK, Anaplastic Lymphoma Kinase; HU, Hounsfield Unit; SD, Standard deviation.

<sup>a</sup>Others include all patients with squamous cell carcinoma and patients with non-squamous carcinoma without specific driver oncogenes (EGFR mutation or ALK rearrangement).

<sup>b</sup>Neutrophil-to-lymphocyte ratios were collected with blood test data just before the initiation of PD-1/PD-L1 inhibitor therapy. Neutrophil-to-lymphocyte ratios were calculated as neutrophils divided by lymphocytes and high NLR was stipulated as ≥5.

<sup>c</sup>Cancer cachexia was defined as an unintentional weight loss >5% during the preceding 6 months or >2% in patients with a BMI <20 kg/m², or the presence of muscle depletion according to consensus criteria.

<sup>d</sup>High muscle quantity was defined based on lumbar skeletal muscle index cutoffs ≥43.0 cm²/m² for men with a BMI <25.0 kg/m², ≥53.0 cm²/m² for men with a BMI ≥25.0 kg/m², and ≥41.0 cm²/m² for women.

<sup>e</sup>High muscle quality was defined based on lumbar skeletal muscle index cutoffs ≥41.0 HU in those with a BMI <25.0 kg/m², and ≥33 HU in those with a BMI ≥25.0 kg/m².
inhibitor monotherapy in patients with NSCLC. We found that high muscle density, as determined by lumbar CT images taken just before the initiation of PD-1/PD-L1 inhibitor therapy, was significantly associated with a high ORR and long PFS duration, irrespective of the degree of PD-L1 expression in the tumor and PS, both of which are established predictors of efficacy in these treatments. On the contrary, with regard to OS, there was no significant association between the therapeutic effects of PD-1/PD-L1 inhibitor and muscle quality or quantity.

Several previous cross-sectional studies have researched the role of muscle quantity in the prediction of PFS or OS with regard to PD-1/PD-L1 inhibitor use in patients with advanced NSCLC. However, the results were inconsistent, with one study reporting the lack of association and three other studies demonstrating positive associations with PFS or OS (Table 3). All of the studies had a retrospective design and included small numbers of patients (23–100 patients). Assessment tools included the cross-sectional area of the psoas or lumbar muscles.

TABLE 2 Predictor for efficacy in PD-1/PD-L1 inhibitors

| Predictors for PFS | Crude HR | 95% CI | p-value | Adjusted HR | 95% CI | p-value |
|--------------------|----------|--------|---------|-------------|--------|---------|
| PD-L1 expressions (TPS≥50% vs. <50% or unknown) | 0.51 | 0.90–1.79 | p < 0.05 | 0.55 | 0.34–0.89 | p < 0.05 |
| ECOG-PS (0–1 vs. 2) | 0.57 | 0.38–0.86 | p < 0.05 | 0.65 | 0.44–0.99 | p < 0.05 |
| Muscle qualitya (High vs. Low) | 0.63 | 0.44–0.89 | p < 0.05 | 0.64 | 0.45–0.92 | p < 0.05 |
| Muscle quantityb (High vs. Low) | 0.98 | 0.68–1.42 | 0.94 | NI | NI | NI |
| Neutrophil-to-lymphocyte ratio c (NLR≥5 vs. NLR<5) | 1.97 | 1.32–2.94 | p < 0.05 | 2.28 | 1.46–3.56 | p < 0.05 |
| Number of prior treatment (one vs. ≥2 regimens) | 1.27 | 0.90–1.79 | 0.18 | NI | NI | NI |

Abbreviations: CI, Confidence interval; ECOG-PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; NI, not include in the multivariate model; NLR, Neutrophil-to-lymphocyte ratio; PFS, progression free survival.

*High and low muscle quality was defined according to muscle attenuation (HU) and BMI. Low muscle quality was defined based on mean attenuation cutoffs <41.0 HU in those with a BMI <25.0 kg/m², and <33.0 HU in those with a BMI ≥25.0 kg/m². There was no difference in the cutoffs between the men and women.

**High and low muscle quantity was defined according to lumbar skeletal muscle index and BMI. Low muscle quantity was defined based on lumbar skeletal muscle index cutoffs <43.0 cm²/m² for men with a BMI <25.0 kg/m², <53.0 cm²/m² for men with a BMI ≥25.0 kg/m², and <41.0 cm²/m² for women.

*Neutrophil-to-lymphocyte ratio was defined as neutrophils divided by lymphocytes, and both neutrophil and lymphocyte counts were based on the results of blood collection immediately before administration of PD-1/PD-L1 inhibitors.

*HR for PD-L1 expression was adjusted for muscle quality, ECOG-PS, and number of prior treatments; HRs for muscle quality and quantity were adjusted for PD-L1 expression, Neutrophil-to-lymphocyte ratio, ECOG-PS, and number of prior treatments.
divided by body height squared. However, three of these studies did not assess the effects of PD-L1 expressions on outcomes.\textsuperscript{14–16} Only one study adjusted for the predictive impact of muscle quantity by PD-L1 expression and reported the absence of an association with PFS,\textsuperscript{17} which is consistent with our study, although the assessment tool used for muscle quantity was different. According to the reports mentioned above and the results of our study, the association between muscle quantity and the therapeutic effects of PD-1/PD-L1 inhibitor therapy remains controversial and needs further evaluation.

Likewise, while the role of low muscle quality in immunotherapy is currently a hot research topic, no conclusions have been drawn to date. While a previous study stated that decreased lumbar muscle density is predictive of inferior PFS in patients with metastatic melanoma treated with ipilimumab,\textsuperscript{25} several other studies conducted in patients with metastatic NSCLC treated with PD-1/PD-L1 inhibitors were skeptical about its predictive value.\textsuperscript{10,17} Cortellini et al. retrospectively reviewed the impact of muscle quality on PFS in association with PD-1/PD-L1 inhibitor use in a mixed cancer population comprising 46 patients with advanced NSCLC and 54 patients with other advanced cancers including renal cell carcinoma and melanoma.\textsuperscript{14} They measured lumbar skeletal muscle density as an indicator of muscle quality and showed no association between muscle quality and PFS or ORR. Minami et al. retrospectively reviewed 74 patients with pretreated and advanced NSCLC who had received PD-1/PD-L1 inhibitor therapy.\textsuperscript{17} They used the intramuscular adipose tissue content in the multifidus muscle as an indicator of muscle quality and showed no association between muscle quality and PFS or ORR patients with PD-1/PD-L1 inhibitor use. The inconsistencies in the results may be attributed to the methodologies used for muscular quality assessment across studies and the heterogeneity of each study population with regard to multi-factors that were possibly associated with cancer cachexia, including levels of inflammation, complications, or age distribution. Additionally, all previous studies including ours have been categorized as retrospective studies and only included a small number of patients in various treatment lines with a different PS value or driver oncogene status. Thus, we believe that adjustments for established confounding factors, including cancer type,\textsuperscript{26,27} PS,\textsuperscript{28} and PD-L1 expression\textsuperscript{29} are essential for estimating the impact of muscular quality on PFS. Our study focused on pretreated patients with advanced NSCLC (n = 156) who were already shown to be refractory to standard chemotherapy or targeted treatment and were naïve to immunotherapy. The predictive impact of muscular quality was tested in the univariate and multivariate analyses, after adjusting for PS and PD-L1 expression. Thus, we propose that muscular quality may be a potential predictor of the therapeutic effects of PD-1/PD-L1 inhibitor therapy; our findings require further validation in future prospective studies.

Decreased muscle quality or myosteatosis is usually assessed by CT density and reflects lipid infiltration in degenerative muscle tissue.\textsuperscript{30} Recently, myosteatosis has been recognized as a strong prognostic factor, independently of muscle quantity, in patients with cancer,\textsuperscript{12} and has been shown to be more sensitive to changes in muscle function than muscle quantity in patients with rheumatoid arthritis\textsuperscript{30} or community-dwelling elderly populations.\textsuperscript{31,32} Therefore, it is possible that our analysis simply reflected the prognostic aspect of muscle quality, and not a predictive aspect. However, we showed significantly higher ORR in the high muscle quality group, and this may support the hypothesis that muscle quality is not only a prognostic factor, but also a predictive factor in immunotherapy. Furthermore, high muscle quality and quantity did not prolong OS in this study, and this result further supports our hypothesis that muscle quality may not be a prognostic factor but a predictive factor.

Although it is unknown why immunotherapy is less efficacious in patients with myosteatosis, several studies have suggested a possible association between myosteatosis, inflammation, and the efficacy of immunotherapy. The presence of myosteatosis has been reportedly associated with elevated inflammatory marker values, including those of tumor necrosis factor (TNF)-α, interleukin (IL)-6, the NLR, and C-reactive protein in humans.\textsuperscript{33–35} IL-6 increases glucocorticoid levels in the serum, which may impair the infiltration and proliferation of CD8+ T cells within the tumor and weaken the therapeutic effects of PD-1/PD-L1 inhibitors.\textsuperscript{9,36} TNF-α not only compromised CD8+ tumor-infiltrating lymphocytes, but also reduced the degree of PD-L1 expression on tumor cells in a murine model of melanoma.\textsuperscript{37} The negative effects of IL-6 on outcomes in cases with PD-1/PD-L1 inhibitor use has been shown in a clinical study of patients with melanoma.\textsuperscript{38} Besides, persistent systemic inflammation induces regulatory T cells and myeloid-derived suppressor cells in tumors, which in turn suppress the levels of antitumor immunocytes, including NK cells, CD8 + T cells, dendritic cells, and B cells, and this eventually promoted tumor progression in experimental models.\textsuperscript{39,40} Furthermore, tumors escape from immune surveillance through the induction of immune checkpoint molecules such as PD-L1 in tumors and CTLA-4 receptors in T cells under the influence of chronic inflammation.\textsuperscript{41,42} Therefore, we hypothesize that decreased muscle quality reflects an increased degree of tumor-associated inflammation, which enhances the resistance against antitumor immunity and results in poor outcomes in PD-1/PD-L1-targeted treatments.

There are some limitations in this study. First, our analysis was limited by its retrospective nature, for which we
were unable to exclude biases associated with unknown factors. Second, the small sample size comprises patients from a single institution, limiting our ability to generalize our results to other populations. Third, we did not measure the level of tumor antigenicity by the tumor mutation burden or microsatellite instability because they are not routinely measured in Japanese clinical practice in advanced NSCLC settings. Fourth, there was a possibility that we could not accurately assess the impact of muscle quality on the OS of patients because it did not directly influence the therapeutic effects of PD-1/PD-L1 inhibitors in patients with various statuses with regard to PS, treatment line, driver oncogene, and presence of cancer cachexia. Finally, this study did not include a control cohort that did not receive immunotherapy, and therefore, it was difficult to make accurate assessments or conclusions regarding predictive roles. A further prospective study is needed to eliminate these biases and patient heterogeneity for the confirmation of our results.

6 | CONCLUSIONS

High lumbar skeletal muscle quality may potentially be used to predict the therapeutic effects of PD-1/PD-L1 inhibitors, independent of PS and PD-L1 expression, in patients with advanced NSCLC. However, further studies are needed to validate our results.
CONFLICT OF INTERESTS
T.N. reported grants from Ono Pharmaceutical Co., Ltd., Pfizer US, Inc., and Mochida Pharmaceutical Co., Ltd. that are outside of the submitted work. H.K. reported grants from Eli Lilly K.K and Taiho Pharmaceutical that are outside the submitted work. S.O. reported grants from Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical, AstraZeneca K.K., Boehringer Ingelheim, Taiho Pharmaceutical, and MSD that are outside the submitted work. K.W. reported grants from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical, Boehringer Ingelheim, Eli Lilly K.K., Ono Pharmaceutical, and MSD that are outside the submitted work. A.O. reported grants from Taiho Pharmaceutical, Ono Pharmaceutical, Chugai Pharmaceutical Co., Ltd., and Novartis Pharma K.K. that are outside the submitted work. H.K. reported grants from Ono Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Bristol-Myers Squibb, MSD, Eli Lilly K.K., Novartis Pharma K.K., Daiichi-Sankyo Co., Ltd., and Pfizer K.K., and grants and personal fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., and Boehringer Ingelheim that are outside the submitted work. H.M. reported grants and personal fees from AstraZeneca, Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical, and Eli Lilly Japan., and grants from Abbvie, Daiichi Sankyo, and IQvia, and personal fees from Ono Pharmaceutical, Bristol-Myers Squibb Japan, and MSD that are outside the submitted work. K.T. reported Lecture fee from AstraZeneca, MSD, Chugai-Roche Co., Ono Pharmaceutical Co., Eli Lilly, Boehringer-Ingelheim Co., and grants from Chugai-Roche Co., Ono Pharmaceutical Co. that are outside the submitted work. T.T. reported grants and personal fees from AstraZeneca KK, Pfizer Japan, Inc., Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., and Boehringer Ingelheim Japan, Inc., and personal fees from Roche Diagnostics K.K. that are outside the submitted work. The other authors have no conflict of interest to declare.

AUTHORS’ CONTRIBUTIONS
Naoya Nishioka and Tateaki Naito Conceptualized the research, designed the study, interpreted the results and wrote the manuscript. Akifumi Notsu and Keita Mori oversaw the analyses as biostatisticians. Hiroaki Kodama, Erik Miyawaki, Taichi Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Kazushige Wakuda, Akira Ono, Hirotugu Kenmotsu, and Haruyasu Murakami: Collected data. Koichi Takayama and Toshiaki Takahashi: Revised the final version of the manuscript.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
This retrospective cohort study was approved by the institutional review board of Shizuoka Cancer Center, Japan (J2019-196), and performed under the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The need for informed consent was waived owing to the retrospective nature of the study.

DATA AVAILABILITY STATEMENT
The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

ORCID
Tateaki Naito https://orcid.org/0000-0003-4047-2929
Haruki Kobayashi https://orcid.org/0000-0002-3386-8063
Shota Omori https://orcid.org/0000-0003-1407-9779
Kazushige Wakuda https://orcid.org/0000-0002-6369-2388
Akira Ono https://orcid.org/0000-0001-5705-9423
Hirotugu Kenmotsu https://orcid.org/0000-0003-0590-9259
Haruyasu Murakami https://orcid.org/0000-0003-2416-546X

REFERENCES
1. Bousoitiis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375:1767–1778.
2. Le D, Kavan P, Kim T, et al. Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability-high (MSI-H) colorectal cancer: KEYNOTE-164. Ann Oncol. 2018;29(Suppl 5):v107.
3. Reck M, Schenker M, Lee KH, et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. Eur J Cancer. 2019;116:137–147.
4. Reck M, Rodriguez-Arue D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019:37:537–546.
5. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819–1830.
6. Bagley SJ, Kothari S, Aggarwal C, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017;106:1–7.
7. Jove M, Vilarino N, Nadal E. Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res. 2019;8:S364–368.
8. Miyawaki T, Naito T, Kodama A, et al. Desensitizing effect of cancer cachexia on immune checkpoint inhibitors in patients with advanced NSCLC. JTO Clin Res Rep. 2020;1:100020.
9. Flint TR, Janowitz T, Connell CM, et al. Tumor-induced IL-6 reprograms host metabolism to suppress antitumor immunity. Cell Metab. 2016;24:672–684.
10. Magri V, Gottfried T, Di Segni M, et al. Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients. Cancer Manag Res. 2019;11:8201–8207.
11. Agelaki S, Rouinis K, Papadaki C, et al. Cancer cachexia, sarcopenia and hand-GRIP strength (HGS) in the prediction of outcome in patients with metastatic non-small cell lung cancer (NSCLC)
treated with immune checkpoint inhibitors (ICIs): a prospective, observational study. J Clin Oncol. 2019;37(15_Suppl):9099.

12. Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31:1539–1547.

13. Nishioka N, Uchino J, Hirai S, et al. Association of sarcopenia with and efficacy of anti-PD-1/PD-L1 therapy in non-small-cell lung cancer. J Clin Med. 2019:8:450.

14. Cortellini A, Bozzetti F, Palumbo P, et al. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study. Sci Rep. 2020:10:1456.

15. Shiroyama T, Nagatomo I, Koyama S, et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: a preliminary retrospective study. Sci Rep. 2019:9:2447.

16. Minami S, Ihara S, Tanaka T, Komuta K. Sarcopenia and visceral adiposity did not affect efficacy of immune-checkpoint inhibitor monotherapy for pretreated patients with advanced non-small cell lung cancer. World J Oncol. 2020:11:9–22.

17. Nishioka N, Uchino J, Hirai S, et al. Association of sarcopenia with and efficacy of anti-PD-1/PD-L1 therapy in non-small-cell lung cancer. J Clin Med. 2019:8:450.

18. Deterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151:193–203.

19. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.

20. Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017:111:176–181.

21. Ferrucci PF, Gandini S, Battaglia A, et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer. 2015:112(12):1904–1910.

22. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–495.

23. Mitropoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1985;1998(85):115–122.

24. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013:48:452–458.

25. Chu MP, Li Y, Ghosh S, et al. Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma. J Cachexia Sarcopenia Muscle. 2020;11:748–755.

26. Suzman DL, Agrawal S, Ning Y-M, et al. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy. Oncologist. 2019:24:563–569.

27. Shitara K, Özgüroğlu M, Bang Y-J, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123–133.

28. Bersanelli M, Briganti M, Buti S, Barni S, Petrelli F. Patient performance status and cancer immunotherapy efficacy: a meta-analysis. Med Oncol. 2018;35:132.

29. Chae YK, Pan A, Davis AA, et al. Biomarkers for PD-1/PD-L1 blockade therapy in non-small-cell lung cancer: is PD-L1 expression a good marker for patient selection? Clin Lung Cancer. 2016;17:350–361.

30. Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol. 1985:2000(89):104–110.

31. Baker JF, Mostoufi-Moah S, Long J, Taratuta E, Leonard MB, Zemel B. Low muscle density is associated with deterioration in muscle strength and physical functioning in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019. https://doi.org/10.1002/acr.24126.

32. Cawthon PM, Fox KM, Gandra SR, et al. Do muscle mass, muscle density, strength, and physical function similarly influence risk of hospitalization in older adults? J Am Geriatr Soc. 2009;57:1411–1419.

33. Miljkovic I, Zmuda JM. Epidemiology of myosteatosis. Curr Opin Clin Nutr Metab Care. 2010;13:260–264.

34. Okugawa Y, Toiyama Y, Yamamoto A, et al. Close relationship between immunological/inflammatory markers and myosteatosis in patients with colorectal cancer: a propensity score matching analysis. J PEN J Parenter Enteral Nutr. 2019;43:508–515.

35. Sueda T, Takahashi N, Nishimura J, et al. Impact of low muscularity and myosteatosis on long-term outcome after curative colorectal cancer surgery: a propensity score-matched analysis. Dis Colon Rectum. 2018;61:364–374.

36. Teng MW, Ngiov SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015:75:2139–2145.

37. Bertrand F, Montfort A, Marchetteau E, et al. TNFalpha blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun. 2017:8:2256.

38. Kottke T, Evgin L, Shim KG, et al. Subversion of NK-cell and TNFalpha immune surveillance drives tumor recurrence. Cancer Immunol Res. 2017:5:1029–1045.

39. Wang D, DuBois RN. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 2015:36:1085–1093.

40. Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? Cancer Sci. 2019:110:2080–2089.

41. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother. 2010:59:1593–1600.

42. Kumar R, Collins D, Dolly S, McDonald F, O’Brian MER, Yap TA. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. Curr Probl Cancer. 2017:41:111–124.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Nishioka N, Naito T, Notsu A, et al. Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer. Cancer Med. 2021;10:247–256. [https://doi.org/10.1002/cam4.3631](https://doi.org/10.1002/cam4.3631)